Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AbbVie
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Study to Evaluate the Safety and Effect of three experimental drugs ABT?450, ABT-267 and ABT-333 in combination with Ribavirin in people who have had a Liver Transplant and have Hepatitis C Virus (HCV) infection. "Experimental" means that they have not been approved by any regulatory agency for sale to the public. Un estudio para evaluar la seguridad y eficacia de tres fármacos experimentales ABT- 450, ABT- 267 y ABT333 administrados junto con Ribavirina en personas con un transplante hepático y con infección crónica por el virus de la hepatitis C (VHC). "Experimental" significa que no han sido aprobados por ninguna agencia reguladora para su venta al público
The primary objectives of this study are to assess safety and efficacy (the percentage of subjects achieving a 12-week sustained virologic response, SVR12 (HCV ribonucleic acid [RNA] < lower limit of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
AbbVie
Update Il y a 4 ans
Étude M12-914 : étude de phase 3, randomisée, en double aveugle, comparant l’efficacité et la tolérance d’un traitement associant le véliparib (ABT-888), un inhibiteur de la PARP, le carboplatine et le paclitaxel par rapport à un traitement associant un placebo, le carboplatine et le paclitaxel, chez des patients ayant un cancer de sein HER2-négatif localement avancé ou métastatique associé à une mutation du gène BRCA, non résécable. [essai clos aux inclusions]
L’objectif de cette étude est de comparer l’efficacité et la tolérance d’un traitement associant le véliparib (ABT-888), un inhibiteur de la PARP, le carboplatine et le paclitaxel par rapport à un tra...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 4, 5, and 6 Infection (SURVEYOR-I)
To assess the efficacy and safety of ABT-493 and ABT-530 with and without ribavirin (RBV) in subjects with chronic HCV genotype (GT) 1, 4, 5, and 6 infection with compensated cirrhosis (GT1 only) or ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
ABT-414 alone or ABT-414 plus temozolomide versus temozolomide or lomustine alone in subjects with recurrent glioblastoma. ABT-414 samostatně nebo ABT-414 s temozolomidem v porovnání s temozolomidem nebo lomustinem samostatně u pacientů s recidivujícím glioblastomem
Overall Survival and Progression Free survival according to RANO criteria and assessed at interim analysis.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa Multicentrické klinické hodnocení účinnosti a bezpečnosti adalimumabu u pacientů se středně těžkou až závažnou hidradenitis suppurativa
To determine the clinical safety and efficacy of adalimumab compared to placebo in subjects with moderate to severe (HS)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease
The primary objective of this interventional study is to examine the effect of LCIG treatment relative to that of Optimized Medical Treatment (OMT) on dyskinesia as measured by the Unified Dyskinesia ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
To evaluate if venetoclax when co-administered with low dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment naïve subjects with acute myeloid leukemia (AML).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with Ulcerative Colitis Who Completed the Study M11-290
The objective of the study is to evaluate the long-term safety, tolerability, and maintenance of clinical response, of repeated administration of adalimumab in pediatric subjects with ulcerative colit...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis Estudio multicéntrico abierto para evaluar la seguridad y eficacia de risankizumab como tratamiento de mantenimiento en la psoriasis en placas de moderada a grave
The primary objective of Study M15-997 is to investigate long-term safety and tolerability of risankizumab in subjects with psoriasis who have completed one of the preceding Phase 2/3 studies. E...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in previously untreated Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy
To evaluate if venetoclax in combination with azacitidine will improve overall survival (OS) and composite complete remission rate (complete remission + complete remission with incomplete marrow recov...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next